Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
Steffen Pfeuffer(Justus-Liebig-Universität Gießen), Sven G. Meuth(University of Würzburg), Konstanze Kleinschnitz(University of Duisburg-Essen), Jens Ingwersen(Heinrich Heine University Düsseldorf), Melanie Korsen(Heinrich Heine University Düsseldorf), Refik Pul, Saskia Räuber(University of Münster), Orhan Aktaş(Heinrich Heine University Düsseldorf), Tobias Ruck(University Hospital Münster), Ludwig Kappos(University of Basel), Hans‐Peter Hartung(The University of Sydney), Alice Willison(Düsseldorf University Hospital), Christoph Kleinschnitz, Leoni Rolfes(University Hospital Münster), Simon Schieferdecker(The University of Sydney)
Cited by 10
Related Papers
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|683
Animal models of ischemic stroke and their application in clinical research
|Drug Design Development and Therapy|2015|639
Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis
|The Journal of Experimental Medicine|2006|447